Two ways to give immunotherapy for advanced melanoma
Part of Cancer, Skin clinical trials.
This study tests two different ways of giving immunotherapy drugs (anti-CTLA-4 and anti-PD-1 checkpoint inhibitors) to treat advanced melanoma that cannot be surgically removed. Researchers want to see if giving one drug through the skin (intradermal) instead of through the vein works as well or better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older with melanoma that is locally advanced, surgically incurable, or has spread to other parts of the body
- Good physical health (ECOG/WHO performance status 0 or 1, meaning you can do most daily activities)
- At least one melanoma lesion on the skin that can be safely biopsied
- Life expectancy of 3 months or more
- Measurable disease: at least one lesion on the skin or lymph node/soft tissue that is at least 10 mm (about 0.4 inches) across on imaging
- Normal or near-normal blood counts, liver function, kidney function, and blood clotting ability
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.